



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 October 2010
EMA/CVMP/223810/2010
Committee for Medicinal Products for Veterinary Use

Post-authorisation summary of opinion*

Circovac

International non-proprietary name (INN): inactivated porcine circovirus type 2

On 13 October 2010, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion,** recommending to grant a variation to the terms of the marketing authorisation for the veterinary medicinal product Circovac. The Marketing Authorisation Holder for this veterinary medicinal product is Merial S.A.S..

The change agreed by the CVMP concerns use of the vaccine in a new target category of animals (piglets).

Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation/extension to the marketing authorisation has been granted by the European Commission.

The scope of the variation applied for was a change in the indication to add the target category of piglets (same species).

* Summaries of opinion are published without prejudice to the Commission Decision.

** Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

